---
title: "Study Guide"
description: "Key concepts, learning objectives, and clinical pearls for Chapter 39: Heart Failure."
weight: 391
type: "docs"
toc: true
showBreadcrumbs: true
showReadingTime: true
---

## Learning Objectives

After completing this chapter, you should be able to:

- Describe the key pathophysiological processes involved in the development and progression of heart failure (HF), including the roles of ventricular remodeling, neurohormonal activation (RAAS and SNS), and natriuretic peptides.
- Differentiate between heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in terms of etiology and primary dysfunction.
- Compare the New York Heart Association (NYHA) functional classification with the American College of Cardiology/American Heart Association (AHA/ACC) staging system for HF, and apply them to patient scenarios.
- Identify common clinical manifestations of HF and correlate them with underlying hemodynamic changes and ventricular dysfunction.
- Outline the primary goals of pharmacotherapy in managing HF, including symptom relief, slowing disease progression, and reducing morbidity and mortality.
- Explain the mechanisms of action, therapeutic effects, and key adverse effects of major drug classes used in HF, such as diuretics, ACE inhibitors/ARBs/ARNIs, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors.
- Discuss the principles of rational drug selection and guideline-directed medical therapy (GDMT) for different stages and types of HF.

## Key Concepts

### 1. Pathophysiology of Heart Failure

A deep understanding of how heart failure develops is crucial for understanding its management. Key processes include ventricular remodeling and the body's own, ultimately harmful, compensatory responses.

- **Initial Injury and Compensation:**
    - Heart failure (HF) begins as a complex clinical syndrome resulting from any heart disorder that makes cardiac output insufficient to meet the body's oxygen demands.
    - In systolic HF, injury to the heart muscle (myocardium) impairs cardiac output, triggering physiological compensatory mechanisms. These include sodium retention to maintain preload and afterload, and an increased heart rate to maintain tissue oxygenation.
- **Ventricular Remodeling:**
    - This is a key pathological process where the heart tries to adapt to increased stress. It involves an increase in wall thickness to decrease wall stress.
    - The cells created during remodeling are often abnormal and include a proliferation of connective tissue, leading to fibrosis.
    - The end result is a change in the left ventricle's structure, causing the chamber to dilate, hypertrophy (thicken), and become more spherical. This process can precede symptoms and contributes to their worsening.
- **Neurohormonal Activation (The Body's Response):**
    - Reduced blood pressure from poor cardiac output triggers two key systems:
        1. **Sympathetic Nervous System (SNS):** The SNS activates to increase heart rate, contractile force, and venous tone. However, chronic activation leads to the downregulation of beta receptors in the heart, making it less responsive to these signals.
        2. **Renin-Angiotensin-Aldosterone System (RAAS):** The RAAS is activated to retain sodium and water, which increases blood volume and preload (the amount of blood returning to the heart).
    - **Long-Term Negative Effects:**
        - **Angiotensin II:** This peptide is a major driver of ventricular remodeling and endothelial dysfunction.
        - **Aldosterone:** Oversecretion of aldosterone leads to fibrosis (scarring) of the ventricular wall.
        - Both the SNS and RAAS are primary targets for HF drug therapy because their long-term effects are detrimental.
- **Natriuretic Peptides (The Counter-Regulatory System):**
    - This system works to counteract the negative effects of the RAAS.
    - Natriuretic peptides promote vasodilation (widening of blood vessels) and diuresis (fluid removal).
    - **B-type natriuretic peptide (BNP)** is a key marker for HF, as it's released from the left ventricle's muscle cells (myocytes) in response to stretching.
    - **Neprilysin** is an enzyme that breaks down and inactivates BNP. Blocking neprilysin is a modern therapeutic strategy to enhance the beneficial effects of natriuretic peptides.

### 2. Differentiating HFrEF and HFpEF

Heart failure is primarily classified based on the left ventricular ejection fraction (LVEF), which is the percentage of blood pumped out of the left ventricle with each beat.

- **Heart Failure with reduced Ejection Fraction (HFrEF):**
    - **Also Known As:** Systolic Dysfunction.
    - **Primary Dysfunction:** The heart muscle's contractility is weakened. The problem is an inadequate force generated to eject blood from the ventricles.
    - **Etiology:** It most commonly occurs after a structural change in the ventricular wall, such as after a heart attack.
    - **Defining Criteria:** LVEF is less than or equal to 40%.
- **Heart Failure with preserved Ejection Fraction (HFpEF):**
    - **Also Known As:** Diastolic Dysfunction.
    - **Primary Dysfunction:** The heart muscle becomes stiff and loses its elasticity, resulting in inadequate relaxation and a slower filling rate.
    - **Etiology:** Often associated with conditions like long-standing hypertension.
    - **Defining Criteria:** LVEF is normal or even high (greater than or equal to 50%), even though overall cardiac output is still reduced.
    - **Note:** Patients with HFrEF can also have features of diastolic dysfunction.

### 3. Classification and Staging Systems

Two systems are used to classify the severity and progression of HF. They are complementary.

| **System** | **Basis of Classification** | **Stages / Classes** |
| --- | --- | --- |
| **New York Heart Association (NYHA) Functional Classification** | Based on the severity of symptoms and limitations on physical activity. It is subjective. | **Class I:** No limitations of physical activity. &lt;br&gt; **Class II:** Slight limitation of physical activity; comfortable at rest. &lt;br&gt; **Class III:** Marked limitation of physical activity; comfortable at rest, but less than ordinary activity causes symptoms. &lt;br&gt; **Class IV:** Unable to carry on any physical activity without discomfort; symptoms present even at rest. |
| **American College of Cardiology/American Heart Association (AHA/ACC) Staging System** | Based on the structural progression of the disease, including at-risk and asymptomatic patients. It is linked to treatments appropriate for each stage. | **Stage A:** At high risk for HF but without structural heart disease or symptoms. &lt;br&gt; **Stage B:** Structural heart disease present, but no symptoms of HF. &lt;br&gt; **Stage C:** Structural heart disease with past or current symptoms of HF. &lt;br&gt; **Stage D:** Refractory (end-stage) HF requiring specialized interventions. |

### 4. Clinical Manifestations of Heart Failure

Symptoms are often caused by either fluid congestion (backup of pressure) or poor perfusion (forward flow failure).

- **General Symptoms:** Common symptoms for any type of HF include breathlessness (dyspnea), fatigue, exercise intolerance, and weight gain due to fluid retention.
- **Left-Sided Heart Failure (Pulmonary Congestion):**
    - **Hemodynamic Change:** Increased pressure and volume in the left ventricle (increased preload) causes pressure to back up into the lungs.
    - **Correlated Symptoms:** This leads to pulmonary symptoms like a persistent cough, dyspnea, orthopnea (shortness of breath when lying flat), and paroxysmal nocturnal dyspnea (waking up suddenly short of breath).
- **Right-Sided Heart Failure (Systemic Venous Congestion):**
    - **Hemodynamic Change:** Often a consequence of untreated left-sided HF, pressure backs up into the systemic venous system.
    - **Correlated Symptoms:** This results in jugular venous distention (bulging neck veins), hepatomegaly (enlarged liver), anorexia, and bilateral dependent peripheral edema (swelling in the legs and ankles).

### 5. Goals of Pharmacotherapy

Drug therapy in HF is multifaceted, aiming to improve both quality and quantity of life.

- **Primary Goals:**
    1. Improvement of symptoms (e.g., reducing congestion and improving exercise tolerance).
    2. Reduction in morbidity (e.g., slowing disease progression and reducing hospitalizations).
    3. Reduction in mortality (i.e., prolonging life).
- **Physiological Goals:**These are the targets for drugs to achieve the primary goals:
    - Decrease cardiac overload (both preload and afterload).
    - Improve contractility of the heart muscle.
    - Decrease the heart rate to improve filling time and reduce myocardial oxygen demand.

### 6. Major Drug Classes in Heart Failure Management

Guideline-directed medical therapy (GDMT) relies on several cornerstone drug classes that target the key pathophysiological pathways.

| **Drug Class** | **Mechanism of Action (MOA) & Therapeutic Effects** | **Key Adverse Effects** |
| --- | --- | --- |
| **Diuretics** | **MOA:** Decrease extracellular fluid volume to reduce preload. **Effect:** Primarily used to relieve symptoms of congestion (e.g., edema, dyspnea). There is no evidence they improve mortality. | Electrolyte imbalances (hypokalemia, hypomagnesemia), volume depletion, hypotension. |
| **ACE Inhibitors (ACEi)** | **MOA:** Inhibit the RAAS by preventing the formation of angiotensin II. **Effect:** Cause vasodilation (reducing preload and afterload) and decrease ventricular remodeling. They improve symptoms, morbidity, and mortality. | Dry "tickle" cough (common reason for discontinuation), hyperkalemia, hypotension, angioedema. |
| **Angiotensin Receptor Blockers (ARBs)** | **MOA:** Inhibit the RAAS by directly blocking angiotensin II from binding to its receptors. **Effect:** Similar to ACE inhibitors; used as an effective substitute in patients who cannot tolerate ACEi (e.g., due to cough). | Hyperkalemia, hypotension. Lower risk of cough and angioedema than ACEi. |
| **Angiotensin Receptor-Neprilysin Inhibitors (ARNIs)** | **MOA:** Combines an ARB (valsartan) with a neprilysin inhibitor (sacubitril). This blocks the RAAS while also increasing levels of beneficial natriuretic peptides. **Effect:** Shown to be superior to ACE inhibitors in reducing HF hospitalizations and mortality. | Hypotension, hyperkalemia. Must not be used within 36 hours of an ACE inhibitor due to angioedema risk. |
| **Beta-Blockers** | **MOA:** Block the effects of the SNS on the heart. **Effect:** Reduce heart rate, decrease ventricular wall tension, and prevent downregulation of beta receptors. Strongly indicated to improve mortality in patients with HFrEF. (Only bisoprolol, carvedilol, and metoprolol succinate are approved for HF treatment). | Bradycardia, hypotension, fatigue. Must be started at a low dose and titrated slowly, especially in acute HF. |
| **Mineralocorticoid Receptor Antagonists (MRAs)** | **MOA:** Block the effects of aldosterone in the kidneys and heart. **Effect:** Prevent sodium retention and decrease myocardial fibrosis. Have been shown to reduce mortality and hospitalizations when added to standard therapy. | Hyperkalemia (must monitor potassium levels), gynecomastia (with spironolactone). |
| **SGLT2 Inhibitors** | **MOA:** Originally diabetes drugs, they block glucose reabsorption in the kidneys, promoting glucose excretion in the urine. **Effect:** Have proven cardiovascular benefits, decreasing mortality and HF hospitalizations in patients both with and without diabetes. | Recommended for use in patients with HF and type 2 diabetes. |

### 7. Rational Drug Selection and Guideline-Directed Medical Therapy (GDMT)

Treatment is based on the patient's stage of HF and specific characteristics. RAAS inhibitors and beta-blockers are the cornerstones of HFrEF therapy.

- **Stage A (At Risk):** Focus is on risk factor modification. Treat hypertension, diabetes, and lipid disorders according to guidelines.
- **Stage B (Structural Disease, No Symptoms):**
    - For patients with HFrEF, GDMT should be initiated to prevent symptoms.
    - An **ACE inhibitor** (or ARB if intolerant) and a **beta-blocker** are recommended.
- **Stage C (Structural Disease with Symptoms):**
    - **HFrEF:**Therapy is layered.
        1. **Foundation:** An **ARNI** is now recommended over an ACEi/ARB for patients in NYHA class II-III to further reduce morbidity and mortality. This is combined with a **beta-blocker** and an **MRA**. An **SGLT2 inhibitor** is also a key component.
        2. **Symptom Control:** **Diuretics** are used as needed to manage fluid retention and congestion.
        3. **Further Therapy:** For specific populations, hydralazine/nitrates (especially in Black patients) or other therapies may be added.
- **Stage D (Refractory HF):**
    - Goals of care are paramount.
    - Continue GDMT and consider advanced options like mechanical circulatory support (MCS), heart transplantation, or palliative/hospice care.
- **HFpEF (Preserved Ejection Fraction):**
    - Evidence for specific drug benefits is limited.
    - Treatment focuses on managing volume overload with **diuretics** and controlling comorbidities like hypertension and atrial fibrillation.

## Clinical Pearls

> [!IMPORTANT]
> **Guideline-Directed Medical Therapy (GDMT) is paramount in HF.** Adherence to GDMT, encompassing clinical evaluation, diagnostics, and tailored pharmacological/procedural interventions, is crucial for maximizing positive outcomes and preventing complications like renal failure and further cardiovascular events.

> [!TIP]
> **Interpreting Natriuretic Peptides:**
> - An NT-proBNP level > 125 pg/mL or a BNP level ≥ 35 pg/mL strongly suggests HF and warrants further diagnostic evaluation.
> - **Key Consideration for ARNIs:** Sacubitril/valsartan (an ARNI) inhibits neprilysin, leading to increased BNP levels. Therefore, NT-proBNP, which is not a substrate for neprilysin, should be used for monitoring HF in patients on ARNI therapy.

> [!NOTE]
> **Differentiating HFrEF and HFpEF:**
> - **HFrEF (Heart Failure with reduced Ejection Fraction):** Characterized by a Left Ventricular Ejection Fraction (LVEF) ≤ 40%. This is typically due to systolic dysfunction (impaired contractility).
> - **HFpEF (Heart Failure with preserved Ejection Fraction):** Characterized by an LVEF ≥ 50%. This is often associated with diastolic dysfunction (impaired ventricular relaxation and filling), though systolic function can also be abnormal. HFpEF diagnosis can be more complex.

> [!NOTE]
> **Aggressively Manage Modifiable Risk Factors:**
> - **Hypertension (HTN):** This is the single most important modifiable risk factor. Effective HTN control can reduce the risk of developing HF by approximately 50%.
> - **Diabetes Mellitus (DM) & Metabolic Syndrome:** Both significantly increase HF risk and adversely affect outcomes if not properly managed. SGLT2 inhibitors have shown particular benefit in patients with DM and HF.

> [!TIP]
> **Evaluating Symptoms: Look for Patterns and Severity:**
> - HF symptoms (e.g., dyspnea, persistent cough, peripheral edema, fatigue) can be vague and overlap with comorbidities.
> - Focus on identifying **clusters of symptoms** and assess for signs of **congestion** (e.g., jugular venous distention, rales, edema) versus **poor perfusion** (e.g., cool extremities, narrow pulse pressure, altered mental status) to guide acute management.
### 1. Pathophysiology of Heart Failure

A deep understanding of how heart failure develops is crucial for understanding its management. Key processes include ventricular remodeling and the body's own, ultimately harmful, compensatory responses.

- **Initial Injury and Compensation:**
    - Heart failure (HF) begins as a complex clinical syndrome resulting from any heart disorder that makes cardiac output insufficient to meet the body's oxygen demands.
    - In systolic HF, injury to the heart muscle (myocardium) impairs cardiac output, triggering physiological compensatory mechanisms. These include sodium retention to maintain preload and afterload, and an increased heart rate to maintain tissue oxygenation.
- **Ventricular Remodeling:**
    - This is a key pathological process where the heart tries to adapt to increased stress. It involves an increase in wall thickness to decrease wall stress.
    - The cells created during remodeling are often abnormal and include a proliferation of connective tissue, leading to fibrosis.
    - The end result is a change in the left ventricle's structure, causing the chamber to dilate, hypertrophy (thicken), and become more spherical. This process can precede symptoms and contributes to their worsening.
- **Neurohormonal Activation (The Body's Response):**
    - Reduced blood pressure from poor cardiac output triggers two key systems:
        1. **Sympathetic Nervous System (SNS):** The SNS activates to increase heart rate, contractile force, and venous tone. However, chronic activation leads to the downregulation of beta receptors in the heart, making it less responsive to these signals.
        2. **Renin-Angiotensin-Aldosterone System (RAAS):** The RAAS is activated to retain sodium and water, which increases blood volume and preload (the amount of blood returning to the heart).
    - **Long-Term Negative Effects:**
        - **Angiotensin II:** This peptide is a major driver of ventricular remodeling and endothelial dysfunction.
        - **Aldosterone:** Oversecretion of aldosterone leads to fibrosis (scarring) of the ventricular wall.
        - Both the SNS and RAAS are primary targets for HF drug therapy because their long-term effects are detrimental.
- **Natriuretic Peptides (The Counter-Regulatory System):**
    - This system works to counteract the negative effects of the RAAS.
    - Natriuretic peptides promote vasodilation (widening of blood vessels) and diuresis (fluid removal).
    - **B-type natriuretic peptide (BNP)** is a key marker for HF, as it's released from the left ventricle's muscle cells (myocytes) in response to stretching.
    - **Neprilysin** is an enzyme that breaks down and inactivates BNP. Blocking neprilysin is a modern therapeutic strategy to enhance the beneficial effects of natriuretic peptides.

### 2. Differentiating HFrEF and HFpEF

Heart failure is primarily classified based on the left ventricular ejection fraction (LVEF), which is the percentage of blood pumped out of the left ventricle with each beat.

- **Heart Failure with reduced Ejection Fraction (HFrEF):**
    - **Also Known As:** Systolic Dysfunction.
    - **Primary Dysfunction:** The heart muscle's contractility is weakened. The problem is an inadequate force generated to eject blood from the ventricles.
    - **Etiology:** It most commonly occurs after a structural change in the ventricular wall, such as after a heart attack.
    - **Defining Criteria:** LVEF is less than or equal to 40%.
- **Heart Failure with preserved Ejection Fraction (HFpEF):**
    - **Also Known As:** Diastolic Dysfunction.
    - **Primary Dysfunction:** The heart muscle becomes stiff and loses its elasticity, resulting in inadequate relaxation and a slower filling rate.
    - **Etiology:** Often associated with conditions like long-standing hypertension.
    - **Defining Criteria:** LVEF is normal or even high (greater than or equal to 50%), even though overall cardiac output is still reduced.
    - **Note:** Patients with HFrEF can also have features of diastolic dysfunction.

### 3. Classification and Staging Systems

Two systems are used to classify the severity and progression of HF. They are complementary.

| **System** | **Basis of Classification** | **Stages / Classes** |
| --- | --- | --- |
| **New York Heart Association (NYHA) Functional Classification** | Based on the severity of symptoms and limitations on physical activity. It is subjective. | **Class I:** No limitations of physical activity. &lt;br&gt; **Class II:** Slight limitation of physical activity; comfortable at rest. &lt;br&gt; **Class III:** Marked limitation of physical activity; comfortable at rest, but less than ordinary activity causes symptoms. &lt;br&gt; **Class IV:** Unable to carry on any physical activity without discomfort; symptoms present even at rest. |
| **American College of Cardiology/American Heart Association (AHA/ACC) Staging System** | Based on the structural progression of the disease, including at-risk and asymptomatic patients. It is linked to treatments appropriate for each stage. | **Stage A:** At high risk for HF but without structural heart disease or symptoms. &lt;br&gt; **Stage B:** Structural heart disease present, but no symptoms of HF. &lt;br&gt; **Stage C:** Structural heart disease with past or current symptoms of HF. &lt;br&gt; **Stage D:** Refractory (end-stage) HF requiring specialized interventions. |

### 4. Clinical Manifestations of Heart Failure

Symptoms are often caused by either fluid congestion (backup of pressure) or poor perfusion (forward flow failure).

- **General Symptoms:** Common symptoms for any type of HF include breathlessness (dyspnea), fatigue, exercise intolerance, and weight gain due to fluid retention.
- **Left-Sided Heart Failure (Pulmonary Congestion):**
    - **Hemodynamic Change:** Increased pressure and volume in the left ventricle (increased preload) causes pressure to back up into the lungs.
    - **Correlated Symptoms:** This leads to pulmonary symptoms like a persistent cough, dyspnea, orthopnea (shortness of breath when lying flat), and paroxysmal nocturnal dyspnea (waking up suddenly short of breath).
- **Right-Sided Heart Failure (Systemic Venous Congestion):**
    - **Hemodynamic Change:** Often a consequence of untreated left-sided HF, pressure backs up into the systemic venous system.
    - **Correlated Symptoms:** This results in jugular venous distention (bulging neck veins), hepatomegaly (enlarged liver), anorexia, and bilateral dependent peripheral edema (swelling in the legs and ankles).

### 5. Goals of Pharmacotherapy

Drug therapy in HF is multifaceted, aiming to improve both quality and quantity of life.

- **Primary Goals:**
    1. Improvement of symptoms (e.g., reducing congestion and improving exercise tolerance).
    2. Reduction in morbidity (e.g., slowing disease progression and reducing hospitalizations).
    3. Reduction in mortality (i.e., prolonging life).
- **Physiological Goals:**These are the targets for drugs to achieve the primary goals:
    - Decrease cardiac overload (both preload and afterload).
    - Improve contractility of the heart muscle.
    - Decrease the heart rate to improve filling time and reduce myocardial oxygen demand.

### 6. Major Drug Classes in Heart Failure Management

Guideline-directed medical therapy (GDMT) relies on several cornerstone drug classes that target the key pathophysiological pathways.

| **Drug Class** | **Mechanism of Action (MOA) & Therapeutic Effects** | **Key Adverse Effects** |
| --- | --- | --- |
| **Diuretics** | **MOA:** Decrease extracellular fluid volume to reduce preload. **Effect:** Primarily used to relieve symptoms of congestion (e.g., edema, dyspnea). There is no evidence they improve mortality. | Electrolyte imbalances (hypokalemia, hypomagnesemia), volume depletion, hypotension. |
| **ACE Inhibitors (ACEi)** | **MOA:** Inhibit the RAAS by preventing the formation of angiotensin II. **Effect:** Cause vasodilation (reducing preload and afterload) and decrease ventricular remodeling. They improve symptoms, morbidity, and mortality. | Dry "tickle" cough (common reason for discontinuation), hyperkalemia, hypotension, angioedema. |
| **Angiotensin Receptor Blockers (ARBs)** | **MOA:** Inhibit the RAAS by directly blocking angiotensin II from binding to its receptors. **Effect:** Similar to ACE inhibitors; used as an effective substitute in patients who cannot tolerate ACEi (e.g., due to cough). | Hyperkalemia, hypotension. Lower risk of cough and angioedema than ACEi. |
| **Angiotensin Receptor-Neprilysin Inhibitors (ARNIs)** | **MOA:** Combines an ARB (valsartan) with a neprilysin inhibitor (sacubitril). This blocks the RAAS while also increasing levels of beneficial natriuretic peptides. **Effect:** Shown to be superior to ACE inhibitors in reducing HF hospitalizations and mortality. | Hypotension, hyperkalemia. Must not be used within 36 hours of an ACE inhibitor due to angioedema risk. |
| **Beta-Blockers** | **MOA:** Block the effects of the SNS on the heart. **Effect:** Reduce heart rate, decrease ventricular wall tension, and prevent downregulation of beta receptors. Strongly indicated to improve mortality in patients with HFrEF. (Only bisoprolol, carvedilol, and metoprolol succinate are approved for HF treatment). | Bradycardia, hypotension, fatigue. Must be started at a low dose and titrated slowly, especially in acute HF. |
| **Mineralocorticoid Receptor Antagonists (MRAs)** | **MOA:** Block the effects of aldosterone in the kidneys and heart. **Effect:** Prevent sodium retention and decrease myocardial fibrosis. Have been shown to reduce mortality and hospitalizations when added to standard therapy. | Hyperkalemia (must monitor potassium levels), gynecomastia (with spironolactone). |
| **SGLT2 Inhibitors** | **MOA:** Originally diabetes drugs, they block glucose reabsorption in the kidneys, promoting glucose excretion in the urine. **Effect:** Have proven cardiovascular benefits, decreasing mortality and HF hospitalizations in patients both with and without diabetes. | Recommended for use in patients with HF and type 2 diabetes. |

### 7. Rational Drug Selection and Guideline-Directed Medical Therapy (GDMT)

Treatment is based on the patient's stage of HF and specific characteristics. RAAS inhibitors and beta-blockers are the cornerstones of HFrEF therapy.

- **Stage A (At Risk):** Focus is on risk factor modification. Treat hypertension, diabetes, and lipid disorders according to guidelines.
- **Stage B (Structural Disease, No Symptoms):**
    - For patients with HFrEF, GDMT should be initiated to prevent symptoms.
    - An **ACE inhibitor** (or ARB if intolerant) and a **beta-blocker** are recommended.
- **Stage C (Structural Disease with Symptoms):**
    - **HFrEF:**Therapy is layered.
        1. **Foundation:** An **ARNI** is now recommended over an ACEi/ARB for patients in NYHA class II-III to further reduce morbidity and mortality. This is combined with a **beta-blocker** and an **MRA**. An **SGLT2 inhibitor** is also a key component.
        2. **Symptom Control:** **Diuretics** are used as needed to manage fluid retention and congestion.
        3. **Further Therapy:** For specific populations, hydralazine/nitrates (especially in Black patients) or other therapies may be added.
- **Stage D (Refractory HF):**
    - Goals of care are paramount.
    - Continue GDMT and consider advanced options like mechanical circulatory support (MCS), heart transplantation, or palliative/hospice care.
- **HFpEF (Preserved Ejection Fraction):**
    - Evidence for specific drug benefits is limited.
    - Treatment focuses on managing volume overload with **diuretics** and controlling comorbidities like hypertension and atrial fibrillation.